Growth hormone secretagogues (GHS) are compounds that stimulate the release of growth hormone (GH) from the pituitary gland through distinct but complementary receptor pathways. CJC-1295 is a long-acting synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective GH secretagogue receptor (GHSR) agonist — often referred to as a “ghrelin mimetic.” In research settings, these two compounds are frequently studied in combination because they act on different receptor populations.
CJC-1295 with DAC (Drug Affinity Complex) extends the plasma half-life of the peptide by binding covalently to serum albumin, resulting in a prolonged GH release profile compared to native GHRH. Ipamorelin, by contrast, is highly selective for GHSR-1a and produces a sharp, pulsatile GH release with minimal effect on cortisol or prolactin — a selectivity profile that has made it a subject of interest for researchers studying the HPG axis and age-related hormonal changes.
Biotidez supplies both CJC-1295 (with and without DAC) and Ipamorelin as lyophilized research peptides, each accompanied by a batch-specific Certificate of Analysis confirming purity and identity. For Research Use Only — Not For Human Consumption.